Vaccine Manufacture and Supply – News and Features

A study has reviewed dozens of evaluations of four COVID-19 vaccines and found that they retain nearly all of their ability to prevent severe disease up to six months after full vaccination.

An inhaled vaccine for SARS-CoV-2 has been shown to provide broad immunity against the virus and is currently in a phase one clinical trial.

Nearly four decades after its discovery, HIV has killed 36.3 million people, with no vaccine in sight. However, a new study takes a promising step in the direction of developing an HIV vaccine.

Scientists at The Wistar Institute have developed a more targeted COVID-19 vaccine that, in animal studies, shows stronger, broader, and more durable protection in a single, low dose.

Researchers have proven that COVID-19 vaccines can be kept ultra-cool for an extended period, providing a resource for safe delivery to remote locations.

Here, we explore some of the reasons behind vaccine hesitancy and highlight potential ways to combat the issue.

Technology Networks spoke with Jonathan Hare, PhD, Imophoron’s Head of Immunology, to learn more about the ADDomer™ vaccine platform, the benefits of administering vaccines by a variety of administrative routes and the infectious diseases they are currently working to develop vaccines for.

Cold-chain distribution requirements complicate vaccine access, reducing vaccination rates for life-threatening, but preventable diseases. Now, researchers have developed a portable production platform for shelf-stable, antibacterial vaccines.

Researchers at Rutgers University have developed a novel approach for delivering DNA therapeutics that relies on suction.

The current standard for women receiving the human papillomavirus (HPV) vaccine is a three-dose regimen, however, a randomized controlled trial of 2,275 women in Kenya has shown that a single dose was highly effective.